Pfizer (NYSE:PFE) reported that its BRAFTOVI combination therapy produced significant progression free survival benefits in ...

Pfizer gets FDA priority review for Hympavzi to treat children 6-11 with hemophilia A or B, expanding current U.S. approvals.

Final results showed factor VIII inhibitor development was not detected among the 72 evaluable pediatric patients. The Food and Drug Administration (FDA) has approved updated labeling for Altuviiio ® ...

If approved, marstacimab would be the first non-factor prophylactic treatment indicated for pediatric patients aged 6 to 11 years with hemophilia B.

TORONTO and CHICAGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that is has completed enrollment in its Phase ...

About a quarter of joints examined had at least 1 joint bleed. Although prophylaxis is the gold standard of treatment for children with hemophilia, a new report highlights the need to vigilantly ...

A nationwide Finnish study of long-term clinical and economic outcomes in real-world pediatric patients with severe hemophilia A showed that early high-dose prophylaxis yielded excellent clinical ...

Hemophilia is a disease that in the past typically affected only children, as the vast majority of affected individuals never reached adult age; it became a greater concern in adults only after the ...

The phase 3, international, open-label, single-group XTEND-Kids study concluded that children with severe hemophilia A younger than 12 years benefited from treatment with efanesoctocog alfa ...

Please provide your email address to receive an email when new articles are posted on . Recombinant Factor IX Fc fusion protein appeared safe and effective in the prevention and treatment of bleeding ...